247 related articles for article (PubMed ID: 20335171)
1. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.
Li C; Chen S; Yue P; Deng X; Lonial S; Khuri FR; Sun SY
J Biol Chem; 2010 May; 285(21):16096-104. PubMed ID: 20335171
[TBL] [Abstract][Full Text] [Related]
2. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
Ma MH; Yang HH; Parker K; Manyak S; Friedman JM; Altamirano C; Wu ZQ; Borad MJ; Frantzen M; Roussos E; Neeser J; Mikail A; Adams J; Sjak-Shie N; Vescio RA; Berenson JR
Clin Cancer Res; 2003 Mar; 9(3):1136-44. PubMed ID: 12631619
[TBL] [Abstract][Full Text] [Related]
3. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
Zheng B; Georgakis GV; Li Y; Bharti A; McConkey D; Aggarwal BB; Younes A
Clin Cancer Res; 2004 May; 10(9):3207-15. PubMed ID: 15131062
[TBL] [Abstract][Full Text] [Related]
4. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
Berenson JR; Ma HM; Vescio R
Semin Oncol; 2001 Dec; 28(6):626-33. PubMed ID: 11740821
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
Hideshima T; Ikeda H; Chauhan D; Okawa Y; Raje N; Podar K; Mitsiades C; Munshi NC; Richardson PG; Carrasco RD; Anderson KC
Blood; 2009 Jul; 114(5):1046-52. PubMed ID: 19436050
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.
Juvekar A; Manna S; Ramaswami S; Chang TP; Vu HY; Ghosh CC; Celiker MY; Vancurova I
Mol Cancer Res; 2011 Feb; 9(2):183-94. PubMed ID: 21224428
[TBL] [Abstract][Full Text] [Related]
7. IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.
Hideshima H; Yoshida Y; Ikeda H; Hide M; Iwasaki A; Anderson KC; Hideshima T
Int J Oncol; 2014 Apr; 44(4):1171-6. PubMed ID: 24481412
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.
Russo SM; Tepper JE; Baldwin AS; Liu R; Adams J; Elliott P; Cusack JC
Int J Radiat Oncol Biol Phys; 2001 May; 50(1):183-93. PubMed ID: 11316563
[TBL] [Abstract][Full Text] [Related]
9. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Zhu H; Zhang L; Dong F; Guo W; Wu S; Teraishi F; Davis JJ; Chiao PJ; Fang B
Oncogene; 2005 Jul; 24(31):4993-9. PubMed ID: 15824729
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
Zou P; Kawada J; Pesnicak L; Cohen JI
J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072
[TBL] [Abstract][Full Text] [Related]
11. Long-term incubation with proteasome inhibitors (PIs) induces IκBα degradation via the lysosomal pathway in an IκB kinase (IKK)-dependent and IKK-independent manner.
Lee KH; Jeong J; Yoo CG
J Biol Chem; 2013 Nov; 288(45):32777-32786. PubMed ID: 24085292
[TBL] [Abstract][Full Text] [Related]
12. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
[TBL] [Abstract][Full Text] [Related]
13. NF-kappa B as a therapeutic target in multiple myeloma.
Hideshima T; Chauhan D; Richardson P; Mitsiades C; Mitsiades N; Hayashi T; Munshi N; Dang L; Castro A; Palombella V; Adams J; Anderson KC
J Biol Chem; 2002 May; 277(19):16639-47. PubMed ID: 11872748
[TBL] [Abstract][Full Text] [Related]
14. Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.
An J; Sun Y; Fisher M; Rettig MB
Mol Cancer Ther; 2004 Jun; 3(6):727-36. PubMed ID: 15210859
[TBL] [Abstract][Full Text] [Related]
15. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
Hideshima T; Richardson P; Chauhan D; Palombella VJ; Elliott PJ; Adams J; Anderson KC
Cancer Res; 2001 Apr; 61(7):3071-6. PubMed ID: 11306489
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
Fribley A; Zeng Q; Wang CY
Mol Cell Biol; 2004 Nov; 24(22):9695-704. PubMed ID: 15509775
[TBL] [Abstract][Full Text] [Related]
17. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
Wang H; Wang X; Li Y; Liao A; Fu B; Pan H; Liu Z; Yang W
Pharmazie; 2012 Feb; 67(2):187-92. PubMed ID: 22512091
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibition in cancer: development of PS-341.
Adams J
Semin Oncol; 2001 Dec; 28(6):613-9. PubMed ID: 11740819
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
Takigawa N; Vaziri SA; Grabowski DR; Chikamori K; Rybicki LR; Bukowski RM; Ganapathi MK; Ganapathi R; Mekhail T
Anticancer Res; 2006; 26(3A):1869-76. PubMed ID: 16827119
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]